

Exhibit C - Table 1, continued

Rte = Route of Administration

TOA = Time of administration

N/A = not applicable

IM = Intramuscular

R.Q = Right quadricep

L.Q = Left quadricep

PBS = Phosphate buffered saline

CONTROL #1 = Plasmid of TEST #1 without HIV-1 coding sequences

CONTROL #2 = Plasmid of TEST #2 without HIV-1 coding sequences

TEST #1 = Expression vector having HIV-1 Z6 envelope gene

TEST #2 = Expression vector having HIV-1 MN envelope gene, rev gene, partial nef gene and partial vpu gene

† Day -1 immediately preceded Day 1; there is no Day 0

\* Each treatment consisted of four intramuscular injections of 0.1 mL volume, two injections at each of two sites, made with the Madajet Excel Medical Injection Gun, Model "M". The test vaccine was Test #1 (1  $\mu$ g/ $\mu$ L formulated with an equal volume (0.6 mL) of bupivacaine (0.5%). Final concentration of the formulated vaccine was 0.5  $\mu$ g/mL.

▲ This treatment consisted of a single intramuscular injection of 1.0 mL volume, at one site, made with a 27 gauge needle and 1 cc syringe. The test vaccine was TEST #2 (100  $\mu$ g/mL).

\* This treatment consisted of two intramuscular injections of 0.5 mL volume, one injection at each of two sites, made with a 27 gauge needle and 1 cc syringe. The test vaccine was TEST #2 (200  $\mu$ g/mL). This treatment was preceded by injection of 0.5 mL bupivacaine (0.25%) one day prior to injection of the test vaccine.

## Exhibit C - Table 1

Animal Number	Pre-treatment				Treatment			
	Substance	Dose	Rte; Site	TOA†	Control	Dose	Rte; Site	TOA
1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
2	Bupivacaine 0.5%	0.5 mL	IM; R.Q.	Days-1, 14, 28, 42, 56, 105, 119	Control #1	100 µg in 0.5 mL	IM; R.Q.	Days 1, 15, 29, 43, 57, 106, 120
	N/A	N/A	N/A	N/A	Control #2	100 µg in 0.5mL	IM; L.Q.	Day 308
	Bupivacaine 0.25%	0.5 mL/site	IM; R.Q. L.Q.	Day 349	PBS	0.5 mL/site	IM; R.Q. & L.Q.	Day 350
3	N/A	N/A	N/A	N/A	TEST #1*	200 µg; 0.4 mL	IM; L.Q., R.Q.	Days 1, 15, 29, 43, 58
	N/A	N/A	N/A	N/A	TEST #2Δ	100 µg; 1.0 mL	IM; R.Q.	Day 200
	Bupivacaine 0.25%	0.5 mL/site	IM; R.Q., L.Q.	Day 241	TEST #2*	100 µg; 1.0 mL	IM; R.Q., L.Q.	Day 242
4	Bupivacaine 0.5%	0.5 mL	IM; R.Q.	Days -1, 14, 28, 42, 56, 105, 119	TEST #1	100 µg in 0.5 mL	IM; R.Q.	Days 1, 15, 29, 43, 57, 106, 120
	N/A	N/A	N/A	N/A	TEST #2	100 µg in 1.0 mL	IM; L.Q.	Day 308
	Bupivacaine 0.25%	0.5 mL	IM; R.Q. L.Q.	Day 349	TEST #2	100 µg in 0.5 mL/site	IM; L.Q. & R.Q.	Day 350
5	Bupivacaine 0.5%	0.5 mL	IM; R.Q.	Days -1, 14, 28, 42, 56, 105, 119	TEST #1	100 µg in 0.5 mL	IM; R.Q.	Days 1, 15, 29, 43, 57, 106, 120
	N/A	N/A	N/A	N/A	TEST #2	100 µg in 1.0 mL	IM; L.Q.	Day 308
	Bupivacaine 0.25%	0.5 mL	IM; R.Q. L.Q.	Day 349	TEST #2	100 µg in 0.5 mL/site	IM; L.Q. & R.Q.	Day 350
6	Bupivacaine 0.5%	0.5 mL	IM; R.Q.	Day-1	TEST #1	100 µg in 0.5 mL	IM; R.Q.	Days 1, 15, 29, 43, 57, 106, 120
	N/A	N/A	N/A	N/A	TEST #2	100 µg in 1.0 mL	IM; L.Q.	Day 308
	Bupivacaine 0.25%	0.5 mL/site	IM; R.Q. L.Q.	Day 249	TEST #2	100 µg in 0.5 mL/site	IM; R.Q. & L.Q.	Day 350